2005 - Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
Abstract
The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.
Assignee Name and Adress: Forest Laboratories, Inc.
New York
NY
What is claimed:
1. A method for treating a mood disorder selected from the group consisting of depression, dysthymia, seasonal affective disorder, bipolar disorder and post-partum depression in a patient, which comprises administering to a patient in need thereof a combination comprising a therapeutically effective: (i) first amount of a compound possessing functional antagonist properties for the N-methyl-D-aspartate (NMDA) receptor complex; and (ii) second amount of a selective serotonin reuptake inhibitor (SSRI) that is citalopram or escitalopram, wherein combination of the first and the second amount is effective to treat the disorder.
2. The method of claim 1, wherein the combination produces a synergistic therapeutic effect.
3. The method of claim 1, wherein the N-methyl-D-aspartate (NMDA) receptor antagonist is a non-competitive NMDA receptor antagonist.
4. The method of claim 3, wherein the NMDA receptor antagonist is memantine or neramexane.
5. The method of claim 4, wherein the SSRI is citalopram and the NMDA receptor antagonist is memantine.
6. The method of claim 4, wherein the SSRI is escitalopram and the NMDA receptor antagonist is memantine.
7. The method of claim 4, wherein the SSRI is citalopram and the NMDA receptor antagonist is neramexane.
8. The method of claim 4, wherein the SSRI is escitalopram and the NMDA receptor antagonist is neramexane.
9. The method of claim 1, wherein at least one of the functional NMDA receptor antagonist and the SSRI compound of part (ii) are administered in a sub-threshhold amount.
10. The method of claim 1, wherein at least one of the functional NMDA receptor antagonist and the compound of part (ii) are administered in a sub-optimal amount.
11. The method of claim 5, wherein the citalopram is administered at a dosage from about 10 to 60 mg/day and the memantine is administered from about 1 to 60 mg/day.
12. The method of claim 11, wherein the citalopram is administered at about 20 to 40 mg/day and the memantine is administered at about 5 to 20 mg/day
13. The method of claim 6, wherein the escitalopram is administered at a dosage from about 1 to 30 mg/day, and the memantine is administered at a dosage from about 1 to 60 mg/day.
14. The method of claim 13, wherein the escitalopram is administered at a dosage of about 5 to 20 mg/day, and the memantine is administered at a dosage from about 5 to 20 mg/day.
15. The method of claim 7, wherein the wherein the citalopram is administered at a dosage from about 10 to 60 mg/day and the neramexane is administered from about 10 to 100 mg/day.
16. The method of claim 15, wherein the citalopram is administered at about 20 to 40 mg/day and the neramexane is administered at about 25-75 mg/day
17. The method of claim 10, wherein the escitalopram is administered at a dosage from about 1 to 30 mg/day, and the neramexane is administered at a dosage from about 10 to 100 mg/day.
18. The method of claim 17, wherein the escitalopram is administered at a dosage of about 5 to 20 mg/day, and the neramexane is administered at a dosage from about 25 to 75 mg/day.
Note:There suggesting (above) using Memantine at 60mg a day.
appft1.uspto.gov |
